Zacks Investment Research downgraded shares of Ablynx N.V. (NASDAQ:ABLYF) from a hold rating to a sell rating in a report published on Monday.

According to Zacks, “Ablynx NV is a biopharmaceutical company which engaged in the development of Nanobodies (R) proprietary therapeutic proteins based on single-domain antibody fragments. The company also discovers and develops therapeutic for inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx NV is headquartered in Ghent, Belgium. “

Shares of Ablynx N.V. (ABLYF) opened at 18.36 on Monday. Ablynx N.V. has a 12-month low of $9.10 and a 12-month high of $50.00. The company’s 50-day moving average is $14.88 and its 200-day moving average is $13.31. The company’s market capitalization is $1.11 billion.

COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Lowers Ablynx N.V. (ABLYF) to Sell” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at

Get a free copy of the Zacks research report on Ablynx N.V. (ABLYF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Ablynx N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ablynx N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.